
Anteris Technologies Global Corp. (AVR) Market Cap
Anteris Technologies Global Corp. has a market capitalization of $288.4M.
Price: $7.84
▼ -0.40 (-4.85%)
Market Cap: 288.42M
NASDAQ · time unavailable
CEO: Wayne Geoffrey Paterson
Sector: Healthcare
Industry: Medical - Devices
IPO Date: 2024-12-13
Website: https://anteristech.com
Anteris Technologies Global Corp. (AVR) - Company Information
Market Cap: 288.42M|Sector: Healthcare
Company Profile
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.
Analyst Sentiment
From 3 Active Polls
1Y Forecast: $18.00
▲ +129.6% Potential Upside
Consensus Target Metrics
Low Bound
$18
Median
$18
High Bound
$18
Average
$18
Price & Moving Averages
🎯 Wall Street Analyst Intelligence Report
1-Year structural target targets, chart projections, and sentiment maps.
Consensus Trend Projection
Trailing closures vs. 12-month metrics map.
Analyst Vote Distribution
Aggregate institutional coverage sentiment weights.
📊 Historical Valuation Multiples
Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.
| Fiscal Quarter | TTM | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Period Ending | Trailing 12M | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 |
| Market Cap ($M) | 288 | 131 | 118 | 106 | 89 | 86 | 132 | 201 | 201 |
| Enterprise Value ($M) | 9 | -149 | 107 | 99 | 64 | 39 | 62 | 194 | 196 |
| Price to Earnings Ratio (P/E) | -1.96 | -1.49 | -1.01 | -1.20 | -1.06 | -0.98 | -1.70 | -2.30 | -2.69 |
| Price/Earnings-to-Growth Ratio (PEG) | — | -0.03 | — | — | -0.10 | -0.26 | — | -0.11 | — |
| Price to Sales Ratio (P/S) | 155.82 | 264.88 | 379.51 | 247.31 | 144.59 | 154.35 | 245.40 | 261.73 | 318.69 |
| Price to Book Ratio (P/B) | 0.66 | 0.47 | -1265.04 | 28.69 | 3.66 | 1.98 | 2.10 | 63.90 | 70.19 |
| Price to Free Cash Flow Ratio (P/FCF) | -3.33 | -4.54 | -6.27 | -5.58 | -4.45 | -3.95 | -7.07 | -13.73 | -14.36 |
| Enterprise Value to Sales (EV/Sales) | — | -300.86 | 346.31 | 231.53 | 103.12 | 69.94 | 116.57 | 252.07 | 310.41 |
| Enterprise Value to EBITDA (EV/EBITDA) | -0.10 | 6.77 | -3.75 | -4.56 | -3.09 | -1.81 | -2.96 | -9.58 | -10.64 |
| Debt to Equity Ratio | 3.01 | 0.01 | -24.54 | 0.64 | 0.12 | 0.05 | 0.02 | 0.86 | 0.66 |
📰 Market News & Coverage
15 Stories AvailableReal-time institutional reporting and market updates for AVR.
Related Companies in Healthcare

INHIBIKASE THERAPEUTICS INC (IKT)
Healthcare
$0.29B
Mkt Cap

SIGHT SCIENCES INC (SGHT)
Healthcare
$0.29B
Mkt Cap

FATE THERAPEUTICS INC (FATE)
Healthcare
$0.29B
Mkt Cap

TREACE MEDICAL CONCEPTS INC (TMCI)
Healthcare
$0.28B
Mkt Cap

ORASURE TECHNOLOGIES INC (OSUR)
Healthcare
$0.28B
Mkt Cap

SCPHARMACEUTICALS INC (SCPH)
Healthcare
$0.30B
Mkt Cap
📊 AI Financial Analysis
Powered by StockMarketInfo"AVR reported Q1’26 revenue of $494k and net loss of -$21.9M (EPS -$0.28), with net margin at -44.4%. QoQ, revenue rose from $310k in Q4’25 to $494k (+59.4%), but profitability remains deeply negative and still unstable: net loss improved only modestly vs Q4’25 (-$29.2M loss), while operating income in Q1’26 was +$1.7M versus a very distressed Q4’25 operating picture (noting Q4’25’s unusually large swings in other income/expense). YoY comparisons show a deterioration in the bottom line: revenue declined from $556k in Q1’25 to $494k (-11.2% YoY) and net loss widened from -$21.9M in Q1’25 to -$21.9M in Q1’26 (roughly flat, but still in loss). Over the four-quarter period, gross margin improved (Q1’26 gross margin 76.9% vs 62.8% in Q1’25), yet net profitability did not follow, indicating heavy drag from below-the-line items (other income/expense) and large operating cost structure driven by R&D. Cash flow remains a key risk: operating cash flow was -$28.7M in Q1’26 (worsening vs -$18.5M in Q4’25). Despite no dividends or buybacks, the company generated substantial financing inflows (+$299.5M other financing), helping liquidity. Balance sheet resilience is mixed: total assets jumped to $294.7M, and cash rose to $283.2M, while retained earnings remain highly negative (-$393.6M), signaling ongoing equity pressure. Total shareholder returns appear strongly positive based on price momentum: the stock is up +112.98% over 1 year, which should materially support the score despite continued losses. Revenue and earnings-based metrics were not applicable for this analysis due to the company's pre-revenue status. The evaluation focused on cash runway, burn rate, and market sentiment instead."
Revenue Growth
Revenue improved QoQ (+59.4% from $310k in Q4’25 to $494k in Q1’26) but declined YoY (-11.2% from $556k in Q1’25). Trend is volatile and not yet translating into sustained profitability.
Profitability
Gross margin expanded (76.9% in Q1’26 vs 70.6% Q4’25 and 62.8% Q1’25), but net margin remains deeply negative (-44.4%). Net losses persist (EPS -$0.28) with significant below-the-line drag.
Cash Flow Quality
Operating cash flow was -$28.7M in Q1’26 (vs -$18.5M in Q4’25), indicating ongoing burn. No dividends; no buybacks reported. Financing inflows (+$299.5M) have been necessary to fund the cash gap.
Leverage & Balance Sheet
Liquidity strengthened sharply: cash and cash equivalents rose to $283.2M and total assets increased to $294.7M. Leverage is low (total debt ~$3.7M; net debt -$279.5M), but retained earnings remain highly negative, implying dependence on continued funding.
Shareholder Returns
Price momentum is strong: +112.98% 1Y change and +22.38% 6M. With no stated dividends or buybacks, total return is likely dominated by capital appreciation.
Analyst Sentiment & Valuation
Limited valuation signal from provided data: price target consensus of $15 sits well above the current price ($6.07), suggesting upside per targets, but persistent losses and cash burn reduce confidence.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.
Fundamentals Overview
📋 Official Regulatory 10-K / 10-Q SEC Filings
Direct authenticated documentation links to audited SEC database reports for AVR.














